NICE publishes draft guidance on betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia for consultation

In DRAFT guidance, NICE does not recommend betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people ≥12 years who do not have a beta0/beta0 genotype, when HSCT is appropriate but a human leukocyte antigen-matched related HSC donor is not available.

National Institute for Health and Care Excellence